Parallel Review: End Of Phase II Could Be Best Time For CMS Involvement

Assuming FDA and CMS move forward with their plan to start parallel reviews of medical products, the end of Phase II trials may be the best time for CMS to start having input in the clinical development process for drugs, a CMS official suggested.